Navigation Links
TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Date:8/27/2007

and we are on track to announce top line results in the fourth quarter of this year. We believe tezampanel represents a potentially new and promising alternative to current treatments for not only migraine but also other pain conditions. Obtaining multiple dose safety and tolerability data will allow us to plan future studies in those chronic painful conditions."

In five Phase IIa, placebo-controlled trials, tezampanel demonstrated proof of concept in multiple pain models. In a placebo and active-controlled clinical trial in patients with acute migraine, the compound, administered intravenously, achieved statistical significance on all primary and secondary endpoints traditionally required for regulatory approval. These endpoints included pain relief at two hours, pain-free at two hours and relief of nausea, photophobia and phonophobia.

About AK Receptor Antagonists

AK receptors are part of the glutamate biological pathway that transmits pain signals to the brain. In addition, these receptors play a critical role in the development of central sensitization phenomena -- a key component of many pain syndromes, including migraine and persistent pain states such as chronic neuropathic pain. AK receptor antagonists selectively bind to certain AK receptors to block transmission of pain signals mediated through the activation of a subtype of glutamate receptors. Because they do not block opioid receptors or constrict blood vessels, the safety profile of AK antagonists may offer important advantages over existing drugs to treat migraine and other pain conditions.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel small molecules to treat diseases and disorders of the central nervous system (CNS). Led by an accomplished management team, TorreyPines is leveraging novel drug targets and technologies to potentially deliver
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015 Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ... million for the three months ended March 31, 2015 ... $22.6 million for the same period in 2014.  Isis, ... from milestone payments earned from its partners compared to ... Isis reported a loss from operations of $9.3 million ...
(Date:5/5/2015)... PORTLAND, Oregon , May 5, 2015 ... market in the US, Europe , ( ... , Spain , UK) and ... and etiology are reviewed. The report provides the 5-year test volume ... Ag, HCV, HCV NAT, Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag, ...
(Date:5/5/2015)... May 5, 2015  Image Stream Medical, a leader ... with MedAssets, one of the largest group purchasing organizations, ... States.  Under terms of the three-year agreement, Image Stream,s ... will be made available to MedAssets members beginning on ... Image Stream Medical CEO Eddie Mitchell said, ...
Breaking Medicine Technology:Isis Reports Financial Results and Highlights for First Quarter 2015 2Isis Reports Financial Results and Highlights for First Quarter 2015 3Isis Reports Financial Results and Highlights for First Quarter 2015 4Isis Reports Financial Results and Highlights for First Quarter 2015 5Isis Reports Financial Results and Highlights for First Quarter 2015 6Isis Reports Financial Results and Highlights for First Quarter 2015 7Isis Reports Financial Results and Highlights for First Quarter 2015 8Isis Reports Financial Results and Highlights for First Quarter 2015 9Isis Reports Financial Results and Highlights for First Quarter 2015 10Isis Reports Financial Results and Highlights for First Quarter 2015 11Isis Reports Financial Results and Highlights for First Quarter 2015 12Isis Reports Financial Results and Highlights for First Quarter 2015 132015 Opportunities in the Global Hepatitis Diagnostic Testing Market: Big Market Research 22015 Opportunities in the Global Hepatitis Diagnostic Testing Market: Big Market Research 3Image Stream Medical Announces Agreement with MedAssets 2
... Conn., Mar. 14, 2011 Biodel Inc. (Nasdaq: ... two new formulations of recombinant human insulin for clinical ... mealtime insulin drug candidates.  The new formulations, BIOD-105 and ... action compared to currently marketed meal time insulin analogs ...
... Inovio Pharmaceuticals, Inc. (NYSE Amex: INO ), ... vaccines against cancers and infectious diseases, announced today that ... initiated a Phase IIb clinical study of its ChronVac-C® ... Inovio,s proprietary electroporation DNA vaccine delivery technology, in combination ...
Cached Medicine Technology:Biodel Announces Accelerated Development Plan for Ultra-Rapid-Acting Insulins: Initiate Phase 2 in 2011; Phase 3 Pivotal Trials in 2012 2Biodel Announces Accelerated Development Plan for Ultra-Rapid-Acting Insulins: Initiate Phase 2 in 2011; Phase 3 Pivotal Trials in 2012 3Biodel Announces Accelerated Development Plan for Ultra-Rapid-Acting Insulins: Initiate Phase 2 in 2011; Phase 3 Pivotal Trials in 2012 4Biodel Announces Accelerated Development Plan for Ultra-Rapid-Acting Insulins: Initiate Phase 2 in 2011; Phase 3 Pivotal Trials in 2012 5Inovio Pharmaceuticals' Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovio's Electroporation Delivery Technology 2Inovio Pharmaceuticals' Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovio's Electroporation Delivery Technology 3Inovio Pharmaceuticals' Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovio's Electroporation Delivery Technology 4Inovio Pharmaceuticals' Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovio's Electroporation Delivery Technology 5
(Date:5/5/2015)... With Mother's Day, graduation and grilling ... country's leading organic vegetable brands, knows exactly what's ... country. What to eat? There’s no need to ... hours browsing Pinterest – Josie's Organics added fresh, ... , The new recipes are sophisticated and easy ...
(Date:5/5/2015)... Tulsa, Oklahoma (PRWEB) May 05, 2015 ... have the money for a fitness membership? Don’t know ... all of these obstacles in order to help members ... greatest life. Live Streaming Fitness, an educational, caused-based wellness ... that offers live streaming fitness classes led by certified ...
(Date:5/5/2015)... NY (PRWEB) May 05, 2015 Sheltering ... and honored Walt “Clyde” Frazier and Cravath, Swaine & ... New York’s highest-need communities. The event was co-chaired by ... Kupferberg. , “The Next Chapter” highlighted Sheltering Arms’ significant ... which was unveiled in February 2015. Formerly Episcopal Social ...
(Date:5/5/2015)... OH (PRWEB) May 05, 2015 Buckeye ... as the new CEO and plan president of Buckeye ... organizations, assumes the position immediately. , Hill has more ... Midwest to the Pacific Northwest, from managed care to ... as president and CEO of HealthPlus of Michigan, a ...
(Date:5/5/2015)... Burnie, MD (PRWEB) May 05, 2015 ... in an upcoming episode of Innovations with Ed Begley ... and show times TBA. , This segment will focus ... home testing. Viewers will learn about their AccuSom® home ... sleep test that provides continuous patient support and next-day ...
Breaking Medicine News(10 mins):Health News:Josie's Organics Kicks Off Mother's Day, Graduation and Grilling Season with New, Easy-to-Follow, Convenient Recipes 2Health News:Josie's Organics Kicks Off Mother's Day, Graduation and Grilling Season with New, Easy-to-Follow, Convenient Recipes 3Health News:Josie's Organics Kicks Off Mother's Day, Graduation and Grilling Season with New, Easy-to-Follow, Convenient Recipes 4Health News:Live Streaming Fitness Creates Industry Shift by Bringing Fitness, Nutrition and Cooking Classes to Smart Devices 2Health News:Live Streaming Fitness Creates Industry Shift by Bringing Fitness, Nutrition and Cooking Classes to Smart Devices 3Health News:Sheltering Arms Honors Walt "Clyde" Frazier and Cravath, Swaine & Moore LLP at Annual Gala 2Health News:Buckeye Health Plan Announces New Chief Executive Officer 2Health News:Buckeye Health Plan Announces New Chief Executive Officer 3Health News:Innovations with Ed Begley, Jr. to Explore NovaSom, Inc., in Upcoming Episode 2
... holiday season, MINNEAPOLIS, Sept. 8 Courage ... new 2008 Courage Cards fine,art holiday greeting card ... anniversary as a holiday card company!, We ... artists:, Bonnie Bahr-Schneider, Wisconsin Rapids, Wis. -- ...
... ANGELES, Sept. 8 Terrell Samuels, CEO of ... newest physician to their,exclusive roster ... fertility specialist ... Hills. Dr. Saadat is a well-respected fertility,specialist in ... excited about the,opportunities to come. In addition they ...
... brain shrinkage, study shows , , MONDAY, Sept. 8 (HealthDay News) ... to be at increased risk of having brain atrophy or ... Alzheimer,s disease and impaired cognitive function. , Although the study, ... can,t confirm that lower levels of B12 actually cause ...
... IKKalpha (IKKα) regulates the cell cycle of keratinocytes and ... cells from becoming malignant, researchers at The University of ... Sept. 9 issue of Cancer Cell. , "We have ... when necessary, halting proliferation of these important cells. In ...
... that drives consumer choices , , MONDAY, Sept. 8 (HealthDay News) ... when using credit cards, gift cards or gift certificates, according ... the September issue of the Journal of Experimental Psychology: ... have to estimate expenses in detail. , "The more ...
... online toolkit to help,health plans reduce racial and ... 8 The National Health Plan,Collaborative has released ... videos to help health plans identify and reduce ... 11 major health insurance plans, in,partnership with organizations ...
Cached Medicine News:Health News:Courage Cards Announces 2008 Fine Art Holiday Greeting Card Collection 2Health News:Courage Cards Announces 2008 Fine Art Holiday Greeting Card Collection 3Health News:Courage Cards Announces 2008 Fine Art Holiday Greeting Card Collection 4Health News:Courage Cards Announces 2008 Fine Art Holiday Greeting Card Collection 5Health News:Courage Cards Announces 2008 Fine Art Holiday Greeting Card Collection 6Health News:Courage Cards Announces 2008 Fine Art Holiday Greeting Card Collection 7Health News:Courage Cards Announces 2008 Fine Art Holiday Greeting Card Collection 8Health News:Vitamin B12 Key to Aging Brain 2Health News:Vitamin B12 Key to Aging Brain 3Health News:Protein 'switch' suppresses skin cancer development 2Health News:Protein 'switch' suppresses skin cancer development 3Health News:Buyers Spend More With Non-Cash Purchases 2Health News:National Health Plan Collaborative Launches Online Toolkit to Assist Health Plans in Reducing Disparities 2
... skin over extended wearing time ... barrier is the barrier of ... Security and confidence assured with ... drain valve that allows regulation ...
Inquire...
Inquire...
Protects the skin over extended wearing time from irritating discharge. Flextend skin barrier is the barrier of choice for urostomies and ileostomies with the added benefit of it being discreet in bo...
Medicine Products: